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Background: 15-Lipoxygenase-2 is linked to atherosclerotic plaque formation; the homologous enzyme 5-lipoxygenase
initiates the synthesis of proinflammatory leukotrienes.
Results:We determined the crystal structure of 15-LOX-2 in the presence of a substrate mimic.
Conclusion: 15-Lipoxygenase-2 and 5-lipoxgenase display active site variations that confer distinct product specificities.
Significance: These differences can be exploited for the design of isoform-specific anti-inflammatories.
Atherosclerosis is associated with chronic inflammation
occurring over decades. The enzyme 15-lipoxygenase-2 (15-
LOX-2) is highly expressed in large atherosclerotic plaques, and
its activity has been linked to the progression ofmacrophages to
the lipid-laden foamcells present in atherosclerotic plaques.We
report here the crystal structure of human15-LOX-2 in complex
with an inhibitor that appears to bind as a substrate mimic.
15-LOX-2 contains a long loop, composed of hydrophobic
amino acids, which projects from the amino-terminal mem-
brane-bindingdomain.The loop is flankedby twoCa2-binding
sites that confer Ca2-dependent membrane binding. A com-
parison of the human 15-LOX-2 and 5-LOX structures reveals
similarities at the active sites, as well striking differences that
can be exploited for design of isoform-selective inhibitors.
Atherosclerosis is one of several pathologies attributed to an
unchecked inflammatory response. A hallmark of the disease is
the deposition of macrophage-derived foam cells in plaques
that grow to restrict vascular blood flow or rupture. Either
event can culminate in one of the various manifestations of
cardiovascular disease such as heart attack or stroke. A critical
component in the development of atherosclerosis is transfor-
mation of macrophages to foam cells, a process involving the
uptake of lipids carried by low-density lipoprotein LDL. The
presence of oxidized lipids in the LDL particles further exacer-
bates the process by provoking the release of inflammatory
cytokines, attracting still more macrophages to the growing
lesion. Mitigation of this inflammatory response can slow the
progression of atherosclerosis.
The enzyme 15-lipoxygenase (15-LOX),3 which is expressed
in macrophages, has been linked to elevated levels of oxidized
lipids through several experimental approaches that include
the heterologous expression of human 15-LOX in a mouse
model of hyperlipidemia (1) and pharmacological inhibition of
15-LOX activity (2, 3). Humans have two 15-LOX (4), desig-
nated types 1 (ALOX15A) or 2 (ALOX15B), and the type 1
isoformwas the formused in the heterologous expression stud-
ies cited above. Mouse knock-out studies with the LOX homo-
logue of 15-LOX-1 support a role for ALOX15A in plaque for-
mation (5). However, it is ALOX15B mRNA that is present in
human macrophages (6, 7) isolated from atherosclerotic
plaques. Furthermore, elevated levels of ALOX15B mRNA are
present in carotid lesions derived from symptomatic, rather
than asymptomatic, subjects. ALOX15AmRNA is not detected
above control levels in either case (6). More recently, Magnus-
son et al. (8) demonstrated that silencing production of the
ALOX15Bprotein inhumanmacrophagesdecreased cellular lipid
accumulation, the precipitating factor in foam cell formation.
Finally, 15S-hydroxyeicosatetraenoic acid (HETE), derived
through non-enzymatic reduction of the product of the
15-LOX reaction, has been shown to promote formation of ath-
erosclerotic lesions in a mouse model system (9).
Lipoxygenases (LOX) are a family of iron enzymes that cata-
lyze the peroxidation of polyunsaturated fatty acids to generate
oxylipins, which in both animals and plants serve essential roles
in signaling (10). The reaction proceeds via abstraction of the
hydrogen from the central carbon of a pentadiene and oxida-
tion of the free radical generated two carbons removed from the
site of attack. Six distinct LOXhave been identified inmammals
(4), and the enzymes are named according to their product
specificities. Thus, 15-LOX converts the common substrate
arachidonic acid (AA) to 15-hydroperoxyeicosatetraenoic acid
(HPETE) by attack at C13 of AA, whereas 5-LOX attacks at C7
to transform AA to 5-HPETE (and, subsequently, 5-HPETE to
inflammatory leukotriene A4). The question of how the AA-
metabolizing enzymes are able to discriminate among the three
chemically equivalent pentadienes of AA to generate a specific
HPETE isomer remains to be clarified.
The various lipid mediators of the cyclooxygenase pathway
can have opposing functions. Similarly, the LOX pathways pro-
duce either pro- or anti-inflammatory compounds. For exam-
ple, 5-LOX alone is responsible for the synthesis of the proin-
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flammatory leukotrienes, but anti-inflammatory lipoxins can
be synthesized by the combined activities of 15- and 5-LOX or
5- and 12-S-LOX. In addition, 15-LOX also synthesizes the
anti-inflammatory neuroprotectin D1 from docosahexaenoic
acid (11). These disparate roles for LOX products make devel-
opment of isoform-specific LOX inhibitors critical in the quest
for novel therapeutics.
LOX structures share the common framework established by
Boyington et al. (12) with the soybean LOX structure. The ani-
mal enzymes, which generally metabolize AA rather than lino-
leic acid or linolenic acid, represent a pared down version of the
fold, as they are650 amino acids in length rather than 950
amino acids. However, both the plant and animal enzymes con-
tain an N-terminal membrane binding domain and a C-termi-
nal catalytic domain.
We report here the crystal structure of human 15-LOX-2 in
complex with a competitive inhibitor that appears to bind as a
substrate mimic. This structure reveals a putative membrane
insertion loop and two Ca2-binding sites also found at the
equivalent positions in 5-LOX. Site-directed mutagenesis sup-
ports a role for the Ca2-binding sites in membrane binding,
and the uniquemembrane insertion loop is poised to play a role
in tethering the enzyme at the bilayer. Moreover, a comparison
of human 15-LOX-2 and 5-LOX structures reveals significant
differences in the highly conserved active sites that can be
exploited for isoform-specific inhibitor design.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Protein Expression—15-LOX-2
was co-expressed in Rossetta 2 (DE3) cells in pET Duet-1 with
Escherichia coli yjgDprotein. The yjgD genewas amplified from
E. coli DNA and cloned behind promoter 2 in pET Duet-1 by
digesting both vector and insert with NdeI and XhoI. The
human 15-LOX-2 cDNA obtained from the ATCC was ampli-
fied with primers containing SpeI and HindIII sites and cloned
behind promoter 1 by digesting the vector with XbaI and
HindIII. After transformation, Rosetta2 cells (Novagen) were
grown as overnight cultures and then diluted (1:100) into 500
ml volumes of Terrific broth (Alpha Biosciences) in 2-liter
Erlenmeyer flasks. After 4 h at 37 °C and 220 rpm, the speedwas
reduced to 150 rpm, and the cells were incubated an additional
27 h at 20 °C for leaky expression of 15-LOX-2. Cells were har-
vested, pelleted, and stored at80 °C.
Protein Purification—Cells were lysed in a mixture of Bug-
buster (Invitrogen) and Problock 2Dprotease inhibitormixture
(Gold Biotechnology); both were used according to the man-
ufacturer’s instructions. DNase I (0.2 mg/ml) (Sigma) was
added, and the suspension was processed in a French pressure
cell. Insolublematerial was removed by centrifugation at 17,500
rpm for 30 min, and imidazole buffer was added to the super-
natant to a final concentration of 20 mM. The sample was
syringe-filtered (0.45 M pore size) and applied to a Co2-ni-
troloacetic acid column (Pierce) equilibrated with buffer A (20
mM Tris-HCl, pH 8.0, 20 mM imidazole, 500 mM NaCl) and
configured on an Akta FPLC (GE Healthcare). Protein was
elutedwith a 0–100% gradient of buffer B (20mMTris-HCl, pH
8.0, 200 mM imidazole, 500 mM NaCl). The major peak eluted
from the column at 30% B. Peak fractions were pooled and
concentrated with a 35-kDa Amicon ultra centrifugal filtration
unit (Sigma) and subsequently applied to Superdex 200 (GE
Healthcare) for gel filtration. SDS-PAGE, enzyme assays, and
product analysis confirmed that themajor peak which eluted at
86 ml corresponded to 15-LOX-2. Protein was concentrated to
10 mg/ml, flash-frozen dropwise in liquid N2, and stored at
80 °C until use.
Crystallization—15-LOX-2 was screened for crystallization
conditions with crystal screens from Hampton and a Gryphon
liquid dispenser (ARI). Conditions yielding crystalline-like
material were further screened varying pH, buffer, cryo-pro-
tectant, and detergent. After extensive additive screening, the
detergent octyltetraethylene glycol ether (C8E4, Anatrace)
proved essential for crystallization. The conditions that yielded
diffraction quality rhombohedral crystalswere 1MNH4SO4, 0.1
M Bis-Tris, pH 5.5, 5% glycerol, and 24 mM C8E4. Crystals were
grown in hanging drops.
Diffraction Data Collection—15-LOX-2 crystals were looped
from the mother liquor and placed directly in the 100 K N2
stream of an Oxford CryoJet or plunged into liquid N2 for ship-
ping. Two x-ray data sets were collected at separate beamlines.
The first data set was collected to a resolution of 2.85 Å at the
Gulf Coast Protein Crystallography Consortium beamline at
the Center for Advanced Microstructures and Devices (Baton
Rouge, LA). The final data set was collected to 2.65 Å at the
24ID-E beamline of the Northeastern Collaborative Access
Team at the Advanced Photon Source (Argonne National Lab-
oratory). This last data set was obtained from a crystal soaked
for 30 min in mother liquor supplemented with 40 mM CaCl2
prior to flash-cooling in liquid N2. HKL2000 (13) was used to
process data collected at the Gulf Coast Protein Crystallogra-
phy Consortium beamline. XDS, pointless, and scala were used
via the RAPD processing suite of the Northeastern Collabora-
tive Access team to process the data collected by theNortheast-
ern Collaborative Access Team.
The Phenix program suite (14) was used to perform molec-
ular replacement (with PHASER) and the model refinement
that followed. Model building was performed in Coot (15). The
structure of Stable-5- LOX (Protein Data Bank 3O8Y) served as
the searchmodel for the 2.85Ådata set. Themodel constructed
with this data set was subsequently used as the searchmodel for
the 2.65 Å data from a CaCl2 soaked crystal. Refinement was
performed with Phenix.refine.
Enzyme Assays—Enzyme activity was monitored in an
Applied Photophysics Model SX.18MV stopped-flow spec-
trometer at 22 °C. Product (15-hydroperoxyeicosatetraenoic
acid) formationwasmonitored at 235nmwith a cell path length
of 0.2 cm. The enzyme concentration was 60 nm in 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl. Assays were performed with
arachidonic acid (Cayman Chemical) concentrations ranging
from 1 to 40 M. The reported concentrations of reagents are
those in the observation cell. Each kinetic trace was the average
of at least three individual measurements. Km and Vmax value
were determined by non-linear regression analysis of a plot of
velocity versus substrate concentration to Equation 1. Vmax is
themaximal velocity, S is the substrate concentration, andKm is
the Michaelis constant.
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Kinetic assays in the presence ofC8E4were performed to deter-
mine the mode of inhibition. In these assays, the concentration
of AA was varied between 1–40 M in the presence of varying
concentrations of C8E4 detergent. The enzyme concentration
was 100 nM. Nonlinear regression was used to analyze the
stopped-flow data (16) obtained as described above. Each data
point is the average of at least three kinetic traces. The data
were fit to Equation 2, where v is the initial velocity, Vmax is the
maximal velocity, S is the substrate concentration, Km is the






Nanodisc Preparation—Nanodiscs were prepared with
MSP1E3D1 and phospholipids as described (17, 18) withminor
modifications. Briefly, plasmid pMSP1E3D1 (Addgene) was
expressed in Rosetta 2 cells in Terrific broth (37 °C) in the pres-
ence of 30 g/ml kanamycin. Expression was induced with 0.5
mM isopropyl 1-thio--D-galactopyranoside at A600 of 1.4, and
the cells were allowed to grow for 3.5 h. The temperature was
lowered to 28 °C 1 h post induction. Cells were pelleted and
lysed by sonication in 50 mM sodium phosphate (7.4), 1 mM
PMSF, 1%Triton X-100. Cell debris was pelleted, and the lysate
was applied to a nickel chelate affinity column. The columnwas
washed with five volumes of 1) buffer C (40 mM Tris (pH 8.0),
300 mMNaCl); 2) plus 1% Triton X-100; 3) plus 50 mM cholate;
4) buffer C, and 5) plus 50 mM imidazole. Protein was eluted
with buffer C containing 300 mM imidazole. MSP1E3D1-con-
taining fractions were pooled, concentrated to at least 5mg/ml,
dialyzed into nanodisc buffer (20mMTris-HCl, pH 7.4, 150mM
NaCl, 0.5 mM EDTA), and lyophilized.
Nanodiscs were prepared from rehydrated MSP aliquots,
and phospholipids were resuspended in nanodisc buffer con-
taining 100mM cholate.Mixtures of phospholipids (3:1 porcine
brain PC, porcine brain PS, Avanti Polar Lipids) and MSP
(160:1) in nanodisc buffer with 25 mM cholate were incubated
for 15 min at room temperature. Cholate removal to induce
nanodisc formation was accomplished with the addition of
Biobeads (0.8 g/ml, Bio-Rad) and incubation at room tempera-
ture for 2 h. Biobeads were removed by centrifugation. Nano-
disc formation and nanodisc binding by 15-LOX-2 were mon-
itored by size exclusion chromatography on a Superose-12
column (GE Healthcare).
RESULTS
A Unique -Hairpin Structure Projects from the Membrane-
binding Domain—The crystal structure of human 15-LOX-2
was determined at 2.65 Å resolution (Rwork/Rfree  16.3/20.3;
Table 1). As expected, 15-LOX-2 displays the typical LOX fold
(Fig. 1, A and B): an amino-terminal -barrel domain, which is
known as a PLAT domain (polycystin-1-lipoxygenase -toxin),
and a significantly larger -helical catalytic domain. The cata-
lytic iron is positioned by the side chains of three invariant
histidines (at positions 373, 378, and 553) and the main chain
carboxyl of the C terminus (Ile676). Human 15-LOX-2 shares
42% sequence identity with human 5-LOX and 38% or less than
that with any other LOX for which a structure has been
reported (19–24).
TABLE 1
Diffraction data and structure refinement
15-LOX-2 (Protein
Data Bank code 4NRE)
(40 mM CaCl2 soak) 15-LOX-2
Data collection
Space group R32 R32
Cell dimensions a 155.79, b 155.79, and
c 263.21 Å;  90,
 90, and 	 120°




Resolution (Å) 38.95–2.63 ( 2.72–2.63) 50.0–2.72 (2.83–2.72)
Rmerge 0.048 (0.39) 0.20 (0.55)
I/
I 14.2 (2.0) 11.95 (1.9)
Completeness (%) 94.07 (68.7) 99.9 (100)
Redundancy 2.6 (2.1) 4.9 (4.7)
Refinement
Resolution (Å) 38.95–2.63 (2.72–2.63)





















a r.m.s.d., root mean square deviation.
FIGURE 1. Overlay of 15-LOX-2 and stable 5-LOX. A, schematic renderings
of 15-LOX-2 (green) and stable5-LOX (pink). Ca2 is shownasblue spheres, and
the catalytic iron is in rust. B, detail of the difference in positioning of helix2.
Side chains from the 5-LOX segment occupy the shallower half of the
15-LOX-2 inhibitor binding site.
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LOXs are cylindrical in overall shape (100 Å in length,45
Å in width), and the PLAT domain is roughly one-third of the
cylinder. In 15-LOX-2, the PLAT domain contains two appar-
ent Ca2-binding sites, the first of which (Ca-l) is located in the
turn at amino acids 39–44. The Ca2 in Ca-1 is coordinated by
Asp39 and Glu44 and the main chain carbonyls of Asn40 and
Gly42 and a water molecule. The second site (Ca-2) appears to
stabilize an12-amino acid loop at Pro74–Ala86 that connects
strands from the two sides of the stacked -sheets of the barrel.
This proline-rich hydrophobic loop projects 20 Å from the
membrane-binding domain as a hairpin-like structure. The
Ca-2 site, which is coordinated by Asp85, the main chain car-
bonyls of Ala86, Gly15, Gly17, and a water molecule, appears to
anchor the C-terminal region of the hairpin loop. The loop is
restrained by a crystal-packing contact in the crystal structure,
as it is nestled at the active site entrance of a neighboring mol-
ecule. Although this interaction may constrain the loop in an
extended fashion, the prolines at its base and within the
sequence also provide rigidity and contribute to its projection
from the body of the protein. The projection of the loop from
the body of the protein is visible in the surface rendering in Fig.
2, A and B.
Phospholipase A2 and human 5-LOX contain highly con-
served calciumbinding sites in their PLATdomains (13, 19, 20).
Although sequence homology is low, the 15-LOX-2 Ca-1 and
Ca-2 binding sites are in equivalent positions with those in
5-LOX, which displays Ca2-dependent membrane binding
(25, 26). The Ca2-binding sites are positioned along one edge
of the PLAT domain, on the same face of the elongated mole-
cule that harbors the entrance to the catalytic site. These obser-
vations led us to test whether Asp39, Glu44, and Asp85 confer
Ca2-dependent membrane binding of 15-LOX-2 (27).
Ca2-dependent Membrane Binding—Ca2-dependent
membrane binding was monitored using nanodiscs as mem-
brane mimics. Nanodiscs with a diameter of110 Å were pre-
pared with membrane scaffold protein E3. In the absence and
presence of Ca2 nanodiscs and 15-LOX-2 elute at 9.7 and
11.2 ml, respectively, on a Superose 12 column (Fig. 2C). In
the absence of Ca2, when co-incubated mixtures are applied
to the sizing column, nanodiscs, and 15-LOX-2 retain their
individual elution volumes. In contrast, with the addition of 2
mM CaCl2 to the elution buffer (which is 0.5 mM EDTA), the
LOX peak shifts to indicate co-elution with nanodiscs. This
same shift was observed in a mutant that lacks Ca-1 (D39A/
E44A). In contrast, a mutant lacking both calcium sites (D39A/
E44A/D85A) eluted at a volume consistent with free enzyme
(Fig. 2C). Mutations of Ca2-binding amino acids does not sig-
nificantly affect enzyme activity (Table 2). All enzymes display
the same kcat, an indication that the catalytic machinery
remains intact. A detail of the Ca-2 site, which anchors the
extended loop, is depicted in Fig. 2D.
The Crystal Structure of 15-LOX-2 Reveals a Novel Inhibitor
Binding in a Substrate-like Conformation—The LOX catalytic
domain is a bundle of 20 helices. Although LOXs share a
common fold and the conformations and placement of the
majority of the helices are conserved, two distinct configura-
tions have been described for the region that constitutes the
second helix (2) in this domain (amino acids 178–199 in
15-LOX-2). In 15-LOX-1 (20), 8R-LOX (23) and 12-LOX (21),
this region is a single -helix that extends nearly the length
of the catalytic domain and rims the active site cavity. In con-
trast, the same segment in the 5-LOX (19) and 11R-LOX (22)
structures is ameandering, broken helix that seals off the cavity.
The structure of human 15-LOX-2 displays the first orienta-
tion: a single -helix that helps define the periphery of the
active site (see Fig. 1). The opposite rim of the active site is
formed by a structurally conserved “arched” helix (amino acids
410–430 in 15-LOX-2).
In the first experimental map calculated with data to 2.8 Å
resolution, a continuous electron density that could not be
attributed to polypeptide was positioned above the catalytic
iron. The polyoxyethylene detergent C8E4, which was required
for diffraction quality crystals, was themost likely candidate for
this density. A molecule of C8E4 was fit into the density such
that the polyoxyethylene tail was innermost and the hydrocar-
bon endmade its way out of the active site through the entrance
portal defined by 2 and the arched helix (Fig. 3A). The higher
sigma value of the innermost electron density most likely rep-
resents the O-rich end of the detergent, but it is not possible to
definitively determine the orientation of C8E4 in the active site.
FIGURE 2. 15-LOX-2 and membrane binding. A, surface rendering of
15-LOX-2. The putative membrane insertion loop projects from the amino-
terminal PLAT domain; prolines present in the loop are colored in red. B, rota-
tion 90° about the horizontal, looking into the active site (C8E4, teal). The
Ca2-binding sites (blue spheres) are on the same face of the molecule as the
active site cavity, which is open to solvent. C, upper panel: in the presence of
Ca2, 15-LOX-2 co-eluteswithnanodiscs.Dashed line, 0.5mMEDTA; solid lines,
plus 2 mM CaCl2. Blue, wild-type; red, D39A/E44A; gray, D39A/E44A/D85A.
Lower panel: for reference, individual elutionprofiles for nanodiscs (ND; black)
and 15-LOX-2 (blue); dashed line, 0.5 mM EDTA; solid line, plus 2.0 mM Ca2. D,
detail of the Ca2-binding site that anchors the insertion loop. Three main






Wild type 1.9 0.37 0.6 0.02
D39A/E44A 1.7 0.16 0.5 0.01
D39A: D3
D39A/E44A/D85A 0.76 0.06 0.6 0.01
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(The Protein Data Bank file contains a second detergent mod-
eled on the surface of the protein. Based on the paucity of con-
tacts it makes with the protein and the high concentration of
detergent in the crystallization buffer, this is likely a nonspecific
protein-detergent interaction.)
The active site C8E4 sits in the cavity in a U-shaped confor-
mation and is surrounded primarily by the side chains of hydro-
phobic amino acids (Fig. 3B). Proximal to the base of the “U” sits
the catalytic iron, held in place by invariant histidines 373, 378,
and 553. Given the shape of the cavity, we asked whether C8E4
might mimic the conformation of the natural substrate AA and
serve as a competitive inhibitor. To test this hypothesis, enzyme
activity was assayed by monitoring the increase in absorbance
(235 nm) of HPETE at varying C8E4 concentrations. The data
were fit to Equation 2. Non-linear regression analysis by the
method of Cleland (16) indicates theKi for C8E4 is 92 (16)M
(Fig. 3C), and the inhibition is competitive. In contrast, a satis-
factory fit to the equation for non-competitive inhibition was
not obtainable.
Modeling of AA in the Active Site—Given that C8E4 compet-
itively inhibits 15-LOX-2, we asked whether the substrate
might fit into the volume occupied by the detergent. Two ori-
entations are possible: one with the carboxyl (“head”) inner-
most and the other the hydrocarbon (“tail”) end innermost.We
refined both orientations in the C8E4 electron density with the
refine ligand option in PHENIX. As can be seen from Fig. 3D,
both fit into the C8E4 density, suggesting that the detergent
bound structure is similar to that of the substrate-bound
structure.
Mechanistic studies have demonstrated that abstraction of
the hydrogen from the central carbon of the pentadiene and
oxidation occur on opposite faces of the AA (see Ref. 28). LOX
structures provide a framework to envision why this is
necessary, as the same amino acids that position the catalytic
iron shield the pentadiene from molecular oxygen (Fig. 3).
Crystal structures of LOX reveal the enzyme resting state in
which in Fe2 occupies the metal binding site. The enzyme
must be activated to Fe3 to proceed with catalysis as it is
Fe3OH that abstracts the H from the pentadiene (see Ref.
29). Note that in Fig. 3E, the Fe2 coordination is completed
with two waters. One of these waters is poised to strike a sub-
strate H on the central carbon of the positioned pentadiene
(Fig. 3E). In the “tail first” fit, this is C13, whereas in the head
first orientation, it is C7.
Fig 4, A and B, provides a view of the relative placements of
the substrate binding site, theO2 channel (30), and the catalytic
iron. Although AA can be modeled in two orientations that are
“inversely” related, only one orientation is consistent with the
product specificity of 15-LOX-2. A schematic provided Fig. 4C
summarizes this information. Note the “inverse” orientations
FIGURE 3. The structure was determined in the presence of a competitive inhibitor. A, omit map (calculated without C8E4) electron density (2Fo Fc, 1
)
positioned above the active site iron is consistent with the detergent C8E4. B, the amino acids that line the active site cavity. Shown is atomic coloring (green,
carbon; red, oxygen; blue, nitrogen), with invariant/highly-conserved amino acids in gray. C, non-linear regression analysis of enzyme activity measured at
varying inhibitor and substrate concentrations. (, 0mM;E, 0.1mM;, 1.0mMC8E4; AA from1 to 40M). The points represent the observed velocities, and the
lines represent thebest fit of thedata toEquation2.D, AA (purpleand yellow stick renderings; red, oxygen) canbemodeled into theC8E4density in two inversely
related orientations. E, detail of the placement of the yellow AA in D. The iron (rust) coordination sphere is filled by His-373, His-378, His-553, the carboxyl
terminus, and two water molecules (red). The hydrogen of the pentadiene is poised for abstraction. The asteriskmarks C13. The inverse fit of AA C7 sits at this
position.
The Structure of 15-Lipoxygenase-2
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ofAAon the left sideof the figure. BothAAs are positioned such
that the iron (red sphere) and O2 channel (blue peanut) are on
opposite sides, but in the upper one, C13 is positioned for attack
and in the lower C7. (It is not possible for either orientation to
slide deeper in the pocket to produce another regiochemistry.)
To produce 15-HPETE, hydrogen abstraction must occur at
C13, which is only possible with tail first entry. Note that
abstraction of the “back” hydrogen dictates oxygenation on the
“front.” The top product is 15-S-HPETE, and the lower product
is 5-S-HEPTE. So the first orientation has both the correct
regio- and stereo-chemistries because 15-LOX-2 generates
15-S-HPETE exclusively. Moreover, 15-LOX-2 can process
phospholipid-esterified AA (31). This observation is not possi-
ble if the carboxyl end were innermost in the site because there
is no room for the phospholipid head group.
In conclusion, thedetergent defines a cavity that can accommo-
date AA with no further conformational changes. Moreover, the
substrate pentadiene centered at C13 is positioned for attack. An
O2 channel lies slightly deeper in the cavity to allow O2 access to
C15. The stereochemistry of the product for this model is what is
observed in vivo. The structure is entirely consistent with tail-first
entry, and inconsistent with head-first entry of substrate.
DISCUSSION
Several lines of evidence indicate a link between 15-LOX activ-
ity and atherosclerosis. Macrophage uptake of oxidized low-den-
sity lipoprotein promotes their progression to lipid-loaded foam
cells that contribute to atherosclerotic plaques, and oxidized low-
density lipoprotein levels correlatewith 15-LOXactivity. Amodel
for howan intracellular enzyme such as 15-LOXcan contribute to
the oxidation of extracellular LDLhas been proposed byHutchins
andMurphy (32).The investigators identified15-LOXproductsof
the cholesterol esters of deuteratedAAand linoleic acid inmacro-
phages incubated with lipid vesicles of cholesterol ester-esterified
arachidonic and linoleic acids. Their results led them to suggest
that the hydroperoxy acid products generated by cytosolic
15-LOX enter into extracellular pools of cholesterol esters and
phospholipids throughboth the continuous remodelingof choles-
terol esters andphospholipids and theconstant traffickingof lipids
among cellular compartments.
Two15-lipoxygenases, with	40% sequence identity anddis-
tinct patterns of expression and product profiles, have been
identified in humans (27, 33). Human 15-LOX-1 generates
15-HPETE, and to a lesser extent 12-HPETE using AA as a
substrate, whereas the product of 15-LOX-2 with AA is exclu-
sively 15-HPETE (33). Recent data implicate the 15-LOX-2 iso-
form in the pathogenesis of atherosclerosis becausemRNA and
protein levels of this LOX have been shown to be high in
human carotid plaques (6). In addition, 15-LOX-2 is
expressed in macrophages (7, 34, 35), and expression is reg-
ulated by hypoxia-inducible factor-1 (35). Moreover, knock-
down of 15-LOX-2 expression in human primarymacrophages
and in mice (in this case, the target was 8-LOX, the murine
homologue of 15-LOX-2) decreased lipid accumulation and
inflammation, hallmarks of atherosclerosis (8).
Our 15-LOX-2 structure revealed a hydrophobic hairpin struc-
ture that projects from the amino-terminal membrane binding
domain. Sequence alignment indicates that this hairpin is unique
to the 15-LOX-2 isoform and could help position the enzyme at
the phospholipid bilayer. Unlike 5-LOX, 15-LOX-2 can process
PC-esterified AA (31). This activity suggests a model in which
translocation to themembrane increases accessibility to substrate
and a tethered enzyme could function at the membrane interface
for utilization ofAA-bearing phospholipidswithout the need for a
lipase, or for re-esterfication of the product for the oxidized prod-
uct to enter the PL trafficking pathways.
Structures for two mammalian homologues of 15-LOX-1
(
80% identity to human 15-LOX-1, but 	40% to 15-LOX-2)
have been reported: one is in the absence and presence of inhib-
itor (20), and the other is the catalytic domain only with inhib-
itor (21). These models serve as reliable templates for human
15-LOX-1. The structures of the two 15-LOX isoforms are
essentially the same in terms of overall fold: 15-LOX-2 super-
imposes with the porcine homologue with an rmsd of 1.62 Å
(552 C) and with the uninhibited rabbit 15-LOX-1 with an
rmsd of 1.9 Å (667C). However, 15-LOX-1 lacks the extended
loop at amino acids 73–85 of 15-LOX-2.
The 15-LOX-2 Inhibitor Defines the Substrate-bound
Conformation—Recall that kinetic data indicate that C8E4 is a
competitive inhibitor. In addition, AA can adopt an equivalent
U-shaped conformation to that of the bound detergent. More-
over, placement of AA tail-first in the C8E4 electron density
positions the pentadiene centered at C13 for attack (Fig. 3, D
and E). This positioning would generate the 15-S product, con-
sistent with the product stereochemistry observed for both
15-LOX isoforms. Furthermore, a channel that would allow the
FIGURE 4.Mechanistic details are consistent with a unique orientation of
AA in the active site. A, the contour of the active site with bound C8E4 is
complementary to AA in shape, and the catalytic iron and apparent oxygen
channel lie on opposite sides of the tunnel. This relationship between O2
channel and catalytic iron is shown clearly in B. C, schematic of the two fits
(Fig. 3D) of AA. The substrate can be modeled it with its tail (top) or head
deepest in the cavity (bottom). The depth of the pocket and the orientation of
the substrate determinewhich pentadiene is positioned for attack. In the top
orientation, the pentadiene at C13 is positioned for attack; in the lower, C7 is
positionedproximal to the red sphere (iron) behind theplane. Theblue peanut
represents the O2 channel slightly deeper in the active site but above the
plane. A single product is produced by each orientation: with the tail end
innermost AA is transformed to 15-S-HPETE, whereas the inverse orientation
results in 5-S-HPETE.
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approach ofO2 to the activated pentadiene (30) is clearly visible
in the surface rendering in Fig. 4. The competitive inhibitor
included in the porcine structure indicates a similar, but slightly
deeper, cavity to allow three more carbons past that catalytic
iron and attack at C10 (the porcine homologue generates
12-HPETE and attacks at C10). In contrast, the rabbit 15-LOX
structure with inhibitor displays a striking conformational
change with 10 Å displacement of helix -2 that likely is
unique to the inhibitor included in the crystallization, a confor-
mationally restrained compound that makes contacts inconsis-
tent with the native substrate. Consequently, the 15-LOX-1:
inhibitor structure provides solid evidence for malleability of
these active sites, and binding site plasticity expands opportu-
nities for isoform-specific inhibitor development.
15-LOX-2 and 5-LOX Differ in the Orientations of Their
Common Substrate—The two structures of human LOX now
available, the15-LOX-2describedhere and stable 5-LOX(19), can
help to formulate novel strategies toward the development of iso-
form-specific inhibitorsbecause theenzymesdisplaydistinctlydif-
ferent active site cavities. A major difference between the two is
that the 5-LOXcavity is sealed off by the atypical placement of2,
whereas that in 15-LOX-2 is open to solvent. The closest homo-
logue to 15-LOX-2 in humans is 5-LOX. Recall that if AA were
positioned head-first in the 15-LOX-2 active site, it would be
transformed to 5-S-HPETE, the 5-LOX product. Extensive bio-
chemical studies have led to a model in which both cavity depth
and head versus tail entry of AA combine to explain the varying
regio-andstereo-isomerspecificitiesofLOXfamilymembers (28).
This model predicts that AA enters 5-LOX head-first. We asked
whether the head-first entry of AA in 15-LOX-2 as illustrated in
Fig. 4C (bottom) might provide insight into how AA binds in
5-LOX. The images and schematic in Fig. 5 reveal that although
the internal portions of the LOX cavities are similar in volume,
they have dissimilar chemistries. Note that with the loss of a Glu,
and thegainof 2His, the innerportionof the5-LOXcavity ismore
positive in overall change. The amino acids that hold the catalytic
iron inplaceandposition thepentadiene for attackarecommonto
both active sites and composed of invariant or highly conserved
amino acids. It is not possible to compare the cavities at the car-
boxyl end of the 15-LOX-2 active site because this end is tightly
corked by Phe177 and Tyr181 in 5-LOX. Although it is tempting to
speculate that this end of the sitemust uncork for AA to enter the
5-LOX active site, these experiments are beyond the scope of this
work.
The Murine Homologue of 15-LOX-2 Is an 8-LOX—15-S-
HETE (generated by non-enzymatic reduction of 15-S-HPETE)
has been shown to be the LOX product that contributes to
atherosclerosis in a murine model system (9). However, silenc-
ing expression ofmurineALOX15B (which produces 8-HPETE
from AA rather than 15-HPETE) mitigated plaque formation
(8). These studies appear to be at odds: the former indicates that
it is the product of a 15-LOX that promotes plaque formation,
whereas one might infer from the latter studies that 8-HETE
should be the proinflammatory lipid mediator in the mouse
model. This apparent contradiction can be reconciled. Again,
the model that proposes that LOX enzymes can differ in terms
of whether AA enters head- or tail-first (28) is invoked here.
Jisaka et al. (36) demonstrated that the difference in products
of 15-LOX-2 and itsmurine counterpart 8-LOX (87% sequence
identity) can be explained by the substitution of Asp602/Val603
with Tyr/His at the equivalent positions in the 8S-enzyme.
Val603 is deep in the 15-LOX-2 cavity (Fig. 3B) where the hydro-
carbon end of the substrate sits, and mutation of the murine
enzyme to the human sequence (a His to Val) at this position
transformed the 8-LOX into a 15-LOX by converting an
enzyme inwhichAA enters head-first (as in 5-LOX) to one that
enters tail first (as in 15-LOX-2).
Recall that 15-LOX-2 can metabolize PC-esterified AA. It has
been reported thatmurine 8-LOXcan also transformphospholip-
id-esterified AA (31). However, the presence of the phospholipid
head groupmakes head-first entry impossible in the 8-LOXactive
site, so the murine enzyme cannot produce the 8S isomer from
PC-AA. Instead,withPC-AAas the substrate, themurine8S-LOX
is forced to accept tail-first entry. Thus with PC-esterified sub-
strate 8-LOX could be a de facto 15-LOX. Given that 15-LOX-2
displays Ca2-dependent membrane binding, and the mouse
homologue includes thoseaminoacids that conferbindingandthe
putativemembrane insertion loop, onemight predict that in vivo,
the murine enzyme can generate PC-esterified 15-HPETE that
ultimately enters the cellular pool of free 15-HETE. It is notewor-
thy thatmurine8-LOXisananomalybecause theotherALOX15B
homologues generate 15-HPETE.
Concluding Remarks—In summary, we report here the struc-
ture of human 15-LOX-2. As expected 5-LOX and 15-LOX-2
share a common framework, a commoncatalytic core, and a com-
monsubstrate.However, the enzymesgeneratedistinct isomersof
the product. A comparison of the structures of active site cavities
FIGURE 5.The substrate binding cavities of 15-LOX-2 and stable 5-LOX.A,
a surface rendering of the inhibitor binding site in 15-LOX-2 reveals a cavity
that can accommodate AA. The catalytic iron is behind the inhibitor (orienta-
tion similar to that in Figs. 3A and 4A), and an apparent O2 channel is on the
upper face (29). B, a similar rendering of the cavity in 5-LOXwith the 15-LOX-2
inhibitor superimposed. Note that the volumes of the cavities beyond the O2
channel are similar, but that 5-LOX is “corked” above the channel by two
amino acids from 2 (Phe177, Tyr181). C, schematic of inverse orientations of
AA (black, tail first). Amino acids that line the cavity in 15-LOX-2 are listedwith
5-LOX counterparts in parentheses. Invariant amino acids are in boldface type.
Amino acid changes that result in an increase in positive change deep in the
cavity of 5-LOX are highlighted in blue.
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of this pair of enzymes, along with an understanding of catalytic
mechanism, provides insights into substrate recognition.
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